这篇综述的目的是评估鼠李糖乳杆菌GG（LGG）（以前称为鼠李糖乳杆菌GG）在定植载体中根除耐万古霉素的屎肠球菌（VREfm）的有效性和安全性。我们搜查了CochraneCentral,EMBASE,和PubMed图书馆从成立到2023年8月21日，进行随机对照试验（RCT），研究LGG根除胃肠道携带VREfm的有效性。进行初步筛选，然后对论文进行全文评估。在原始筛选的4076篇文章中，6项RCT(167名参与者)纳入审查.均为安慰剂对照的随机对照试验。关于LGG清除VREfm定植的作用，荟萃分析尚无定论。由于不一致和试验中的患者数量少，证据的总体质量较低。我们发现没有足够的证据支持在定殖携带者中使用LGG根除VREfm。在未来的试验中需要具有标准化的LGG制剂和剂量的更大的RCT。
The aim of this
review was to assess the efficacy and safety of Lacticaseibacillus rhamnosus GG (LGG) (previously known as Lactobacillus rhamnosus GG) for the eradication of vancomycin-resistant Enterococcus faecium (
VREfm) in colonized carriers. We searched Cochrane Central, EMBASE, and the PubMed Library from inception to 21 August 2023, for randomized controlled trials (RCTs) investigating the effectiveness of LGG for the eradication of gastrointestinal carriage of
VREfm. An initial screening was performed followed by a full-text evaluation of the papers. Out of 4076 articles in the original screening, six RCTs (167 participants) were included in the
review. All were placebo-controlled RCTs. The meta-analysis was inconclusive with regard to the effect of LGG for clearing
VREfm colonization. The overall quality of the evidence was low due to inconsistency and the small number of patients in the trials. We found insufficient evidence to support the use of LGG for the eradication of VREfm in colonized carriers. There is a need for larger RCTs with a standardized formulation and dosage of LGG in future trials.
PDF(Pubmed)